Navigation Links
Ardea Biosciences to Present at Two Upcoming Investor Conferences
Date:3/5/2010

SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that the Company will present at the following investor conferences during the month of March 2010:

  • Cowen and Company 30th Annual Health Care Conference in Boston, Massachusetts. Barry D. Quart, Pharm.D., president and chief executive officer, will present at 1 p.m. EST on Monday, March 8, 2010.  This presentation will be webcast and can be accessed on the Investor Center section of Ardea's website at www.ardeabio.com.
  • Roth 22nd Annual Orange County Growth Stock Conference in Dana Point, California. John W. Beck, senior vice president, finance and operations and chief financial officer, will present at 11 a.m. PDT on Monday, March 15, 2010.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV).  RDEA594, our lead product candidate in development for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development.  Our next-generation URAT1 inhibitor, RDEA684, is currently in preclinical development.  RDEA119, a potent and specific inhibitor of mitogen-activated ERK kinase (MEK), is being developed under a global license agreement with Bayer HealthCare AG.  RDEA119 is currently being evaluated in advanced cancer patients with different tumor types as a single agent in a Phase 1 study, as well as in combination with sorafenib (Nexavar®, Bayer HealthCare, Onyx Pharmaceuticals, Inc.) in a Phase 1/2 study.  RDEA806, for the treatment of HIV, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has successfully completed a Phase 2a study in HIV patients.  RDEA427, a next generation NNRTI, has superior pharmacokinetic properties, and even greater activity against a wide range of drug-resistant viral isolates than RDEA806.  We have evaluated RDEA427 in a human micro-dose pharmacokinetic study.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, RDEA684, RDEA119, RDEA806, RDEA427 and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs and risks related to the outcome of our business development activities, including collaboration or licensing agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO)

SOURCE Ardea Biosciences, Inc.

Back to top

RELATED LINKS
http://www.ardeabiosciences.com

'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
2. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
4. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
5. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
6. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
7. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
8. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , July 21, 2017  Endo International plc ... completing a comprehensive review of its manufacturing network, the ... and distribution facilities in Huntsville, Alabama ... take place over the next 12 to 18 months. ... impacted by declining volumes of commoditized products and these ...
(Date:7/19/2017)... , July 19, 2017  Mako Medical Laboratories ... and the Military Family Assistance Fund (MFA) to bring ... to visit with their families one last time ... to coordinate the travel and logistics needed for these ... deployed soldiers and their families. We just wish we ...
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
Breaking Medicine Technology:
(Date:7/22/2017)... , ... July 21, 2017 , ... Reassured For Life ... brokerage firm servicing Albertans,” says owner and licensed broker Nerissa McNaughton. “I launched this ... be difficult, but it is a very necessary conversation. I make it easy. As ...
(Date:7/22/2017)... (PRWEB) , ... July 22, 2017 , ... ... patients with irreparable rotator cuff repairs the opportunity to return to sports and ... American Orthopaedic Society for Sports Medicine’s Annual Meeting in Toronto, Ontario, ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Bryant ... to families and business owners in the Dalton region, is working in conjunction ... overcoming sexual assault and physical abuse. , The GreenHouse is headquartered in Dalton ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie provider ... in a community wide charity event with the goal of bringing in support for ... woman who lives with epilepsy, recently launched a charity campaign of her own by ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... insurance assistance and financial planning services to communities in the greater Birmingham area, ... to provide resources to underprivileged young people in the region. , The Chris ...
Breaking Medicine News(10 mins):